Cytokinetics (CYTK) Accounts Payables (2010 - 2026)

Cytokinetics (CYTK) has reported Accounts Payables for 17 consecutive years, with $24.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables rose 77.23% year-over-year to $24.7 million; the TTM figure through Mar 2026 stood at $24.7 million (up 77.23% YoY), while the FY2025 annual figure was $22.3 million, up 9.66% from the prior year.
• Accounts Payables grew to $24.7 million in Q1 2026 per CYTK's latest filing, from $22.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $25.6 million in Q4 2022 and bottomed at $9.5 million in Q2 2024.
• Historically, Accounts Payables has averaged $17.2 million across 5 years, with a median of $16.2 million in 2025.
• Annual changes were most pronounced in 2022 — Accounts Payables jumped 155.42% — and 2024, when it slipped 25.29%.
• Cytokinetics' Accounts Payables stood at $25.6 million in 2022, then slipped by 16.02% to $21.5 million in 2023, then retreated by 5.29% to $20.4 million in 2024, then gained by 9.66% to $22.3 million in 2025, then gained by 10.62% to $24.7 million in 2026.
• Business Quant data shows CYTK's Accounts Payables at $24.7 million in Q1 2026, $22.3 million in Q4 2025, and $22.1 million in Q3 2025.